Spectrum Pharmaceuticals (SPPI) Receiving Somewhat Positive Media Coverage, Study Shows
News headlines about Spectrum Pharmaceuticals (NASDAQ:SPPI) have been trending somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Spectrum Pharmaceuticals earned a daily sentiment score of 0.12 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 46.7932514796142 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Here are some of the media stories that may have effected Accern’s analysis:
- Should You Sell Spectrum Pharmaceuticals (SPPI) Before Earnings? (finance.yahoo.com)
- Bogle Investment Management L P DE Has $12.13 Million Holdings in Spectrum Pharmaceuticals, Inc. (SPPI) (americanbankingnews.com)
- Spectrum Pharmaceuticals: What’s Next For Poziotinib – Seeking Alpha (seekingalpha.com)
- Experts Analysis: Spectrum Pharma Inc (SPPI) – AppsforPCdaily (appsforpcdaily.com)
- $34.00 Million in Sales Expected for Spectrum Pharmaceuticals, Inc. (SPPI) This Quarter (americanbankingnews.com)
A number of equities analysts recently issued reports on the stock. Zacks Investment Research upgraded shares of Spectrum Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, January 12th. B. Riley assumed coverage on shares of Spectrum Pharmaceuticals in a research report on Monday, December 18th. They issued a “buy” rating and a $26.00 target price for the company. HC Wainwright increased their target price on shares of Spectrum Pharmaceuticals to $33.00 and gave the company a “buy” rating in a research report on Monday, February 5th. Finally, BidaskClub lowered shares of Spectrum Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 3rd. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $22.83.
Spectrum Pharmaceuticals Company Profile
Spectrum Pharmaceuticals, Inc is a biotechnology company. The Company operates through developing and commercializing oncology and hematology drug products segment. It has a product portfolio consisting of both commercial stage and development stage products that address various cancer types. The Company has six approved oncology/hematology products that target different types of cancer, including non-Hodgkin’s lymphoma (NHL), advanced metastatic colorectal cancer (mCRC), acute lymphoblastic leukemia (ALL) and multiple myeloma (MM).
Receive News & Ratings for Spectrum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectrum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.